Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases

Abstract

To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises (A) δ-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination. R 2 R 1 NCH 2 COCH 2 CH 2 COR 3   (1) wherein R 1 and R 2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R 3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.

1 . A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises:
 (A) a δ-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof; and   (B) an iron compound:
   R 2 R 1 NCH 2 COCH 2 CH 2 COR 3    (1) 
   
     wherein R 1  and R 2  each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R 3  represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group. 
   
   
       2 . The therapeutic agent for a mitochondrial dysfunction brain disease according to  claim 1 , wherein (B) the iron compound is one or two or more compounds selected from ferric chloride, iron sesquioxide, iron chlorophyllin sodium, ferritin iron, ferrous citrate, sodium iron citrate, ammonium iron citrate, ferrous fumarate, ferrous pyrophosphate, ferric pyrophosphate, saccharated iron oxide, iron acetate, iron oxalate, ferrous succinate, sodium iron succinate citrate, heme iron, dextran iron, iron lactate, ferrous gluconate, sodium iron diethylenetriaminepentaacetate, ammonium iron diethylenetriaminepentaacetate, sodium iron diethylenediaminetetraacetate, ammonium iron diethylenediaminepentaacetate, triethylenetetramine iron, sodium iron dicarboxymethylglutamate, ammonium iron dicarboxymethylglutamate, choline iron citrate, ferrous formate, ferric formate, ammonium ferric potassium oxalate, ferrous sulfate, ferric sulfate, ammonium iron sulfate, ferric carbonate, ferrous chloride, and iron oxide. 
   
   
       3 . The therapeutic agent for a mitochondrial dysfunction brain disease according to  claim 1  or  2 , wherein the mitochondrial dysfunction brain disease is amyotrophic lateral sclerosis, mitochondria myopathy, migraine, Parkinson's disease, hypoxic encephalopathy, cerebral arteriosclerosis, manic-depressive psychosis, chronic fatigue syndrome, intracranial hypertension, normal pressure hydrocephalus, cerebral vasospasm after subarachnoid hemorrhage, prevention of cerebral ischemia at surgery and intravascular surgery, atherothrombotic cerebral infarction, lacunar infarction, cardiogenic cerebral embolism, or Alzheimer's disease. 
   
   
       4 . A diagnostic agent for a mitochondrial dysfunction brain disease, which comprises a δ-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof:
   R 2 R 1 NCH 2 COCH 2 CH 2 COR 3    (1)   
     wherein R 1  and R 2  each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R 3  represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group. 
   
   
       5 . The diagnostic agent for a mitochondrial dysfunction brain disease according to  claim 4 , wherein the mitochondrial dysfunction brain disease is amyotrophic lateral sclerosis, mitochondria myopathy, migraine, Parkinson's disease, hypoxic encephalopathy, cerebral arteriosclerosis, manic-depressive psychosis, chronic fatigue syndrome, intracranial hypertension, normal pressure hydrocephalus, cerebral vasospasm after subarachnoid hemorrhage, prevention of cerebral ischemia at surgery and intravascular surgery, atherothrombotic cerebral infarction, lacunar infarction, cardiogenic cerebral embolism, or Alzheimer's disease.